当前位置： SCI文献检索 > World Journal of Clinical Cases期刊下所有文献 > Considerations for routine coagulation monitoring with rivaroxaban: A case report and review of the literature.

Considerations for routine coagulation monitoring with rivaroxaban: A case report and review of the literature.

Abstract：

BACKGROUND:Rivaroxaban is a non-vitamin K antagonist oral anticoagulant that does not require coagulation monitoring based on current recommendations. Our goal is to explore whether routine coagulation monitoring should not be required for all patients receiving oral rivaroxaban, what relationship between routine coagulation abnormalities and bleeding, and how to deal with the above clinical situations through our case and review of the literature. CASE SUMMARY:We report a 67-year-old woman with a history of atrial fibrillation who presented to the hospital with worsening dyspnea and cough. Based on electrocardiogram, venous compression ultrasonography, and computed tomography pulmonary angiography, the diagnosis of atrial fibrillation, deep venous thrombosis, and acute pulmonary embolism was confirmed. Her coagulation assays and renal function were normal on admission; she was not underweight, did not have a history of hemorrhagic disease, and her CHA2DS2-VAS, HAS-BLED, and simplified Pulmonary Embolism Severity Index scores were 3, 0, and 0, respectively. Oral rivaroxaban (15 mg twice daily) was administered. The following day, she presented gastrointestinal and gum bleeding, combined with coagulation abnormalities. Following cessation of rivaroxaban, her bleeding stopped and tests improved over the next 2 d. Rivaroxaban was begun again 3 d after recovery. However, she again presented with gastrointestinal and gum bleeding and the abnormal tests, and the therapy was discontinued. At 30-d follow-up after discharge, she presented normal coagulation tests without bleeding. CONCLUSION:Although current guidelines recommend that using non-vitamin K antagonist oral anticoagulants including rivaroxaban do not require coagulation monitoring, a small number of patients may develop routine coagulation test changes and bleeding during rivaroxaban therapy, especially in the elderly. Clinicians should pay attention to these patients and further obtain evidence in practice.

journal_name

World J Clin Cases

journal_title

World journal of clinical cases

authors

Wu HD,Cao HY,Song ZK,Yang S,Tang ML,Liu Y,Qin L

doi

10.12998/wjcc.v7.i3.382

subject

Has Abstract

pub_date

2019-02-06 00:00:00

pages

382-388

issue

issn

2307-8960

journal_volume

pub_type

在线工具

Considerations for routine coagulation monitoring with rivaroxaban: A case report and review of the literature.